Medication info

Janutine Duo Tablet 50/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
In-house packaging unit
Approval status
Expired

MFDS item code 201505824 · Approved 2015.08.20

This product's status changed to Expired on 2025.08.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined with consideration of the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining sitagliptin and metformin. It is used alongside dietary and exercise therapy to effectively improve blood sugar levels.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined with consideration of the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is a combination product containing sitagliptin and metformin. Severe allergic reactions may occur while taking this medication; if skin rashes, breathing difficulties, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. Additionally, severe adverse effects such as pancreatitis can occur, so if sudden abdominal pain, nausea, vomiting, or fever arise, seek medical attention immediately. This medication should not be administered to patients with severe renal impairment, dehydration, serious infections, or heart failure, and should be temporarily discontinued during radiological contrast examinations. It is not recommended for use in pregnant women or nursing mothers as safety has not been established. During treatment, be aware of signs of hypoglycemia, especially when used in conjunction with other hypoglycemic agents like insulin or sulfonylureas, as the risk of hypoglycemia may increase. Due to the metformin component, lactic acidosis, a rare but serious metabolic disorder, may occur; if sudden fatigue, muscle pain, breathing difficulties, or abdominal pain arise, seek immediate medical attention. Regular renal function and blood tests should be conducted while taking this medication, and monitoring for vitamin B12 deficiency is also necessary. Alcohol can increase the risk of side effects, so excessive drinking should be avoided while on this medication. If surgery is planned, the medication should be stopped 48 hours prior to the procedure and resumed only after normal renal function is confirmed post-surgery. Safety and efficacy have not been sufficiently established for children, and elderly patients should have dosage adjustments and careful monitoring due to risks of decreased renal function. Finally, if sudden joint pain or blisters on the skin occur during treatment, inform a doctor immediately and seek treatment.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that is air-tight, ideally at room temperature between 1 to 30 degrees. Proper storage will help maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

In-house packaging unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.